Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Limited’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs.

T1 Tumor limited to the pancreas and size <2 cm T2 Tumor limited to the pancreas and size 2–4 cm T3 Tumor limited to the pancreas and size >4 cm or invading duodenum or bile duct T4 Tumor ...

Objectives: To construct a multiphase contrast-enhanced CT-based radiomics nomogram that combines traditional CT features and radiomics signature for predicting the invasiveness of pancreatic solid ...

NEW – Tell your representative to support $25M in research funding! FY25 funding has been eliminated from the only federal program exclusively researching pancreatic cancer – a program YOU helped ...

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.